The Headache Inducing Effects of Cilostazol on Migraine Patients
Information source: Danish Headache Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Migraine
Intervention: Cilostazol (Drug); Placebo (Drug)
Phase: N/A
Status: Completed
Sponsored by: Danish Headache Center
Summary
We will use Cilostazol as a tool to investigate its headache inducing effects in migraine
patients.
Clinical Details
Official title: The Headache Inducing Effects of Cilostazol on Migraine Patients
Study design: Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research
Primary outcome: The incidens of headache or migraine after adminstration of Cilostazol in migraine patients compared to placebo.
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Diagnosed with migraine without aura according to the IHS criteria from 2004.
- Healthy besides migraine
Exclusion Criteria:
- Tension-type headache more than 3 days per month
- Other types of primary headaches
- Pregnancy
- History of vascular diseases or psychiatric diseases.
Locations and Contacts
Danish Headache Center & Department of Neurology, Copenhagen, Glostrup 2600, Denmark
Additional Information
Starting date: April 2013
Last updated: June 5, 2014
|